Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $120.40. The company's market cap stands at 151.68B, with a P/E ratio of 19.08 and a dividend yield of 2.5%.
On 2025-12-13, Gilead Sciences(GILD) stock traded between a low of $119.53 and a high of $123.63. Shares are currently priced at $120.40, which is +0.7% above the low and -2.6% below the high.
The Gilead Sciences(GILD)'s current trading volume is 6.77M, compared to an average daily volume of 6.73M.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $88.57 at its lowest and $128.70 at its peak.
GILD News
Looking at the universe of stocks we cover at Dividend Channel, on 12/15/25, Gilead Sciences Inc (Symbol: GILD), Merck & Co Inc (Symbol: MRK), and Horace Mann E...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel , our YieldBoo...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield In...
Analyst ratings
72%
of 29 ratingsMore GILD News
Gilead Sciences, Inc. ( ) is about to trade ex-dividend in the next four days. The ex-dividend date occurs one day before the record date, which is the day on w...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Gilead Sciences and keeping the price target at $135.00. TipRanks Cyber Monday Sale Claim 60%...
Kite, a Gilead (GILD) Company, presented a new analysis demonstrating that second-line Yescarta therapy offers consistent benefits in patients with relapsed/ref...
If you are wondering whether Gilead Sciences is still attractively priced today or whether most of the upside is already reflected in the share price, this arti...